Mercer Global Advisors
GSK icon

Mercer Global Advisors’s GSK GSK Stock Holding History

Mercer Global Advisors’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.17M Sell
155,769
-91
-0.1% -$4.81K 0.01% 645
2026
Q1 		$8.6M Sell
155,860
-5,023
-3% -$272K 0.01% 553
2025
Q4 		$9.45M Buy
160,883
+26,168
+19% +$1.22M 0.01% 503
2025
Q3 		$5.81M Buy
134,715
+17,120
+15% +$669K 0.01% 617
2025
Q2 		$4.76M Sell
117,595
-2,408
-2% -$92K 0.01% 581
2025
Q1 		$4.88M Sell
120,003
-20,084
-14% -$735K 0.01% 546
2024
Q4 		$4.74M Sell
140,087
-16,258
-10% -$585K 0.01% 549
2024
Q3 		$6.37M Buy
156,345
+8,760
+6% +$358K 0.01% 439
2024
Q2 		$5.79M Buy
147,585
+516
+0.4% +$21.7K 0.02% 417
2024
Q1 		$6.3M Buy
147,069
+16,514
+13% +$681K 0.02% 405
2023
Q4 		$4.84M Sell
130,555
-11,565
-8% -$415K 0.01% 477
2023
Q3 		$5.15M Buy
142,120
+58,022
+69% +$2.06M 0.02% 428
2023
Q2 		$3M Buy
84,098
+25,301
+43% +$908K 0.01% 600
2023
Q1 		$2.03M Buy
58,797
+12,958
+28% +$453K 0.01% 672
2022
Q4 		$1.61M Buy
45,839
+6,584
+17% +$219K 0.01% 743
2022
Q3 		$1.16M Buy
+39,255
New +$1.49M 0.01% 792
2022
Q2 		– Sell
-99,022
Closed -$5.39M – 1862
2022
Q1 		$5.39M Buy
99,022
+11,888
+14% +$646K 0.03% 366
2021
Q4 		$4.8M Buy
87,134
+37,492
+76% +$1.95M 0.03% 390
2021
Q3 		$2.37M Sell
49,642
-2,736
-5% -$137K 0.02% 554
2021
Q2 		$2.61M Buy
52,378
+5,706
+12% +$274K 0.02% 492
2021
Q1 		$2.08M Sell
46,672
-5,298
-10% -$240K 0.02% 511
2020
Q4 		$2.39M Sell
51,970
-12,689
-20% -$583K 0.03% 382
2020
Q3 		$3.04M Buy
64,659
+1,301
+2% +$65.2K 0.05% 292
2020
Q2 		$3.23M Sell
63,358
-10,734
-14% -$551K 0.06% 237
2020
Q1 		$3.51M Sell
74,092
-31,695
-30% -$1.69M 0.08% 216
2019
Q4 		$6.21M Sell
105,787
-4,987
-5% -$277K 0.12% 144
2019
Q3 		$5.91M Buy
110,774
+16,209
+17% +$834K 0.14% 133
2019
Q2 		$4.73M Buy
94,565
+4,686
+5% +$235K 0.13% 144
2019
Q1 		$4.7M Buy
+89,879
New +$4.49M 0.17% 112

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Mercer Global Advisors's GSK Position: Q2 2026 in Review

Mercer Global Advisors reduced its GSK (GSK) stake by 0.06% in Q2 2026, selling an estimated $4.81K and leaving 155,769 shares worth $8.17M. The position accounts for 0.01% of the portfolio, ranked #645.

Mercer Global Advisors first reported a position in GSK in Q1 2019 and has held it in 29 quarters since. The position peaked at $9.45M in Q4 2025. 1,041 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Mercer Global Advisors held 155,769 shares of GSK worth $8.17M as of Q2 2026.
  • Mercer Global Advisors sold 91 GSK shares in Q2 2026, an estimated $4.81K.
  • GSK made up 0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #645 holding.
  • Mercer Global Advisors first reported a position in GSK in Q1 2019 and has held it in 29 quarters since.
  • Mercer Global Advisors's GSK position peaked at $9.45M in Q4 2025.
  • 1,041 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.